ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Vertex Pharmaceuticals Incorporated 

275 Armand-Frappier

Laval  Quebec  H7V 4A7  Canada
Phone: 450-978-7700 Fax: 450-978-7972


SEARCH JOBS




The Science of Possibility.

Vertex Canada is home to innovators in biopharmaceutical research and development. We employ approximately 60 professionals at our research facility in Laval, Quebec, including approximately 45 scientists focused on drug discovery and development activities.

Vertex’s Canadian team is focused on research activities related to inflammatory bowel diseases (IBD), which include Crohn’s Disease and ulcerative colitis. Vertex Canada features a diverse scientific team covering all of our major disciplines and fosters strong cross-functional teams between departments.

Our workplace reflects the rich multiculturalism of the area, which our employees point to as a key advantage of working here. Scientists and researchers from our Laval location have strong collaborative relationships with academic institutions in the area, as well as with our other Vertex locations worldwide.

As part of Vertex’s global network of science research, the Laval site is positioned to continue its quarter century of Canadian contribution to discovering new possibilities in medicine and advancing Canada’s scientific research workforce.

For more information on Vertex, please visit www.vrtx.com. For information on career opportunities with Vertex Canada, please visit www.careers.vrtx.com/.


 Key Statistics


Email:
Ownership: Public

Web Site: Vertex Pharmaceuticals Incorporated
Employees:
Symbol: VRTX
 









 Company News
Royalty Pharma Buys Royalties On Vertex Pharmaceuticals Incorporated (VRTX) Drugs For $3.3 Billion 11/19/2014 5:47:18 AM
Vertex Pharmaceuticals Incorporated (VRTX) To Present At The Credit Suisse Healthcare Conference On November 11 10/31/2014 8:56:44 AM
Vertex Pharmaceuticals Incorporated (VRTX) Reports Third Quarter 2014 Financial Results 10/29/2014 8:50:50 AM
Vertex Pharmaceuticals Incorporated (VRTX) To Present At Morgan Stanley (MST) Global Healthcare Conference On September 10 9/3/2014 1:51:40 PM
Vertex Pharmaceuticals Incorporated (VRTX) Receives European Approval For KALYDECO™ (ivacaftor) In Eight Non-G551D Gating Mutations 8/1/2014 10:27:36 AM
Vertex Pharmaceuticals Incorporated (VRTX) Reports Second Quarter 2014 Financial Results And Provides Updates On Key Research And Development Programs 7/30/2014 10:41:59 AM
Vertex Pharmaceuticals Incorporated (VRTX) To Announce First Quarter 2014 Financial Results On May 1 4/11/2014 6:42:20 AM
Vertex Pharmaceuticals Incorporated (VRTX) Reviews Corporate Strategy And Outlines Key 2014 Business Priorities At The 32nd Annual J.P. Morgan Healthcare Conference 1/13/2014 6:57:42 AM
Vertex Pharmaceuticals Incorporated (VRTX) Announces Appointment Of Jeffrey A. Chodakewitz, M.D., As Chief Medical Officer And Senior Vice President Of Global Medicines Development 1/9/2014 6:57:58 AM
Vertex Pharmaceuticals Incorporated (VRTX) To Present At Upcoming Investor Conferences 11/12/2013 10:17:47 AM
123456